Genetic influences on susceptibility to oxygen-induced retinopathy

Investigative Ophthalmology and Visual Science

Volumn 48, Issue 4, 2007, Pages 1761-1766

  Van Wijngaarden, Peter ^a   Brereton, Helen M ^a   Coster, Douglas J ^a   Williams, Keryn A ^a,b  

^a FLINDERS UNIVERSITY   (Australia)

^b FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; OXYGEN; RNA; GRIFFONIA SIMPLICIFOLIA LECTINS; MESSENGER RNA; PLANT LECTIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; FEMALE; GENETIC SUSCEPTIBILITY; GRIFFONIA; HYPEROXIA; NEWBORN; NONHUMAN; PIGMENTATION; PRIORITY JOURNAL; PROGENY; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RETINOPATHY; STAINING; VASCULAR ENDOTHELIUM; ANIMAL; DISEASE MODEL; FISCHER 344 RAT; GENETIC PREDISPOSITION; GENETICS; HUMAN; INBREEDING; METABOLISM; PEDIGREE; RETINA; RETINA BLOOD VESSEL; RETROLENTAL FIBROPLASIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN PIGMENTATION;

ANIMALS; ANIMALS, NEWBORN; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; ERYTHROPOIETIN; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPEROXIA; INBREEDING; INFANT, NEWBORN; OXYGEN; PEDIGREE; PLANT LECTINS; RATS; RATS, INBRED F344; RETINA; RETINAL VESSELS; RETINOPATHY OF PREMATURITY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SKIN PIGMENTATION;

EID: 34248364805     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.06-0531     Document Type: Article

References (45)

1. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity: three-month outcome. Arch Ophthalmol. 1990;108:195-204.
2. Palmer EA, Flynn JT, Hardy RJ, et al. Incidence and early course of retinopathy of prematurity: the Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology. 1991;98:1628-1640.
3. Schaffer DB, Palmer EA, Plotsky DF, et al. Prognostic factors in the natural course of retinopathy of prematurity: the Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology. 1993;100:30-37.
4. Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of pre-maturity randomized trial. Arch Ophthalmol. 2003;121:1684-1694.
5. Good WV, Hardy RJ, Dobson V, et al. Early Treatment for Retinopathy of Prematurity Cooperative Group: the incidence and course of retinopathy of prematurity: findings from the early treatment for retinopathy of prematurity study. Pediatrics. 2005;116:15-23.
6. Zacharias L. Retrolental fibroplasia: a survey. Am J Ophthalmol. 1952;35:1426-1454.
7. Kinsey VE, Jacobus JT, Hemphill FM. Cooperative study of retrolental fibroplasia and the use of oxygen. Arch Ophthalmol. 1956;56:481-529.
8. Silverman WA. A cautionary tale about supplemental oxygen: the albatross of neonatal medicine. Pediatrics. 2004;113:394-396.
9. Askie LM, Henderson-Smart DJ. Restricted versus liberal oxygen exposure for preventing morbidity and mortality in preterm or low birth weight infants. Cochrane Database Syst Rev. 2001;CD001077.
10. Ng YK, Fielder AR, Shaw DE, Levene MI. Epidemiology of retinopathy of prematurity. Lancet. 1988;2:1235-1238.
11. Tadesse M, Dhanireddy R, Mittal M, Higgins RD. Race, Candida sepsis, and retinopathy of prematurity. Biol Neonate. 2002;81:86-90.
12. Saunders RA, Donahue ML, Christmann LM, et al. Racial variation in retinopathy of prematurity: the Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol. 1997;115:604-608.
13. Lang DM, Blackledge J, Arnold RW. Is Pacific race a retinopathy of prematurity risk factor? Arch Pediatr Adolesc Med. 2005;159:771-773.
14. Darlow BA, Hutchinson JL, Henderson-Smart DJ, et al. Prenatal risk factors for severe retinopathy of prematurity among very preterm infants of the Australian and New Zealand Neonatal Network. Pediatrics. 2005;115:990-996.
15. Vannay A, Dunai G, Banyasz I, et al. Association of genetic polymorphisms of vascular endothelial growth factor and risk for proliferative retinopathy of prematurity. Pediatr Res. 2005;57:96-98.
16. Cooke RW, Drury JA, Mountford R, Clark D. Genetic polymorphisms and retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2004;45:712-715.
17. Hiraoka M, Berinstein DM, Trese MT, Shastry BS. Insertion and deletion mutations in the dinucleotide repeat region of the Norrie disease gene in patients with advanced retinopathy of prematurity. J Hum Genet. 2001;46:178-181.
18. Haider MZ, Devarajan LV, Al-Essa M, Kumar H. A C597-A polymorphism in the Norrie disease gene is associated with advanced retinopathy of prematurity in premature Kuwaiti infants. J Biomed Sci. 2002;9:365-370.
19. Wheatley CM, Dickinson JL, Mackey DA, Craig JE, Sale MM. Retinopathy of prematurity: recent advances in our understanding. Arch Dis Child Fetal Neonatal Ed. 2002;87:F78-F82.
20. Reynaud X, Dorey CK. Extraretinal neovascularization induced by hypoxic episodes in the neonatal rat. Invest Ophthalmol Vis Sci. 1994;35:3169-3177.
21. Madan A, Penn JS. Animal models of oxygen-induced retinopathy. Front Biosci. 2003;8:1030-1043.
22. van Wijngaarden P, Coster DJ, Brereton HM, Gibbins IL, Williams KA. Strain-dependent differences in oxygen-induced retinopathy in the inbred rat. Invest Ophthalmol Vis Sci. 2005;46:445-452.
23. Floyd BN, Leske DA, Wren SM, Mookadam M, Fautsch MP, Holmes JM. Differences between rat strains in models of retinopathy of prematurity. Mol Vis. 2005;11:524-530.
24. Chan-Ling T. Glial, vascular, and neuronal cytogenesis in whole-mounted cat retina. Microsc Res Tech. 1997;36:1-16.
25. Hayes CE, Goldstein IJ. An alpha-D-galactosyl-binding lectin from Bandeiraea simplicifolia seeds: isolation by affinity chromatography and characterization. J Biol Chem. 1974;249:1904-1914.
26. Cunningham S, McColm JR, Wade J, Sedowofia K, McIntosh N, Fleck B. A novel model of retinopathy of prematurity simulating preterm oxygen variability in the rat. Invest Ophthalmol Vis Sci. 2000;41:4275-4280.
27. Roze, S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. In: Krawetz S, Misener S, eds. Bioinformatics Methods and Protocols - Methods in Molecular Biology. Totowa, NJ: Humana Press; 2000:365-386.
28. Ririe KM, Rasmussen RP, Wittwer CT. Product differentiation by analysis of DNA melting curves during the polymerase chain reaction. Anal Biochem. 1997;45:154-160.
29. Sokal RR, Rohlf FJ. Biometry: The Principles and Practice of Statistics in Biological Research. 3rd ed. New York: Freeman; 1995.
30. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3:7research0034.1-0034.11.
31. Zhang S, Leske DA, Holmes JM. Neovascularization grading methods in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2000;41:887-891.
32. Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA. 1993;90:4304-4308.
33. Ribatti D, Presta M, Vacca A, et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood. 1999;93:2627-2636.
34. Morita M, Ohneda O, Yamashita T, et al. HLF/HIF-2alpha is a key factor in retinopathy of prematurity in association with erythropoietin. EMBO J. 2003;22:1134-1146.
35. Blaszczyk WM, Arning L, Hoffmann KP, Epplen JT. A tyrosinase missense mutation causes albinism in the Wistar rat. Pigment Cell Res. 2005;18:144-145.
36. Akeo K, Ebenstein DB, Dorey CK. Dopa and oxygen inhibit proliferation of retinal pigment epithelial cells, fibroblasts and endothelial cells in vitro. Exp Eye Res. 1989;49:335-346.
37. Akeo K, Tanaka Y, Okisaka S. A comparison between melanotic and amelanotic retinal pigment epithelial cells in vitro concerning the effects of L-dopa and oxygen on cell cycle. Pigment Cell Res. 1994;7:145-151.
38. Ilia M, Jeffery G. Retinal mitosis is regulated by dopa, a melanin precursor that may influence the time at which cells exit the cell cycle: analysis of patterns of cell production in pigmented and albino retinae. J Comp Neurol. 1999;405:394-405.
39. Blaszczyk WM, Straub H, Distler C. GABA content in the retina of pigmented and albino rats. Neuroreport. 2004;15:1141-1144.
40. Tombran-Tink J, Johnson LV. Neuronal differentiation of retinoblastoma cells induced by medium conditioned by human RPE cells. Invest Ophthalmol Vis Sci. 1989;30:1700-1707.
41. Gao G, Li Y, Fant J, Crosson CE, Becerra SP, Ma JX. Difference in ischemic regulation of vascular endothelial growth factor and pigment epithelium-derived factor in brown Norway and Sprague-Dawley rats contributing to different susceptibilities to retinal neovascularization. Diabetes. 2002;51:1218-1225.
42. Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science. 1999;285:245-248.
43. Gao G, Li Y, Zhang D, Gee S, Crosson C, Ma J. Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization. FEBS Lett. 2001;489:270-276.
44. Rohan RM, Fernandez A, Udagawa T, Yuan J, D'Amato RJ. Genetic heterogeneity of angiogenesis in mice. FASEB J. 2000;14:871-876.
45. Chan CK, Pham LN, Chinn C, et al. Mouse strain-dependent heterogeneity of resting limbal vasculature. Invest Ophthalmol Vis Sci. 2004;45:441-447.